Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 11 March 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The reasons were that grant income came to be presented as non-operating income rather than business revenue, AMED public funding was used, research and development expenses were reduced by approximately ¥29 million, and business expenses other than research and development expenses were reduced by approximately ¥33 million.
| Item | Details |
|---|---|
| Net Sales | ¥95 million → ¥68 million（-28.2%） |
| Operating profit | ¥-425 million → ¥-356 million |
| Ordinary income | ¥-386 million → ¥-300 million |
| Profit attributable to owners of the parent | ¥-387 million → ¥-301 million |
| Net income per share | -30.09 yen and sen → -23.39 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 11 March 2026 |
| Previous-period results | Business revenue: ¥132 million; operating profit: ¥(178) million; ordinary profit: ¥(178) million; net income: ¥113 million; net income per share: ¥8.92 (fiscal year ended March 2025) |
| Reason for the revision | The reasons were that grant income came to be presented as non-operating income rather than business revenue, AMED public funding was used, research and development expenses were reduced by approximately ¥29 million, and business expenses other than research and development expenses were reduced by approximately ¥33 million. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business revenue decreased because grant income came to be presented as non-operating income rather than business revenue. Meanwhile, research and development expenses were reduced by approximately ¥29 million through the use of AMED public funding for the development of a CML treatment and the containment of research and development expenses in the pancreatic cancer treatment and veterinary pharmaceutical pipelines. Business expenses other than research and development expenses were also reduced by approximately ¥33 million.